Last reviewed 2026-05-25 · How we verify

MEDIBAZINE

Phase 2 active Small molecule ✓ Verified May 2026

MEDIBAZINE is a medibazine drug. It is currently in Phase 2 development.

Medibazine works by interacting with a specific target in the body to produce a therapeutic effect.

MEDIBAZINE is a small molecule with synonyms including MEDIBAZINA, MEDIBAZINE, S-4105, and S4105.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	MEDIBAZINE
Drug class	medibazine
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and medibazine is a key that fits into those locks. When it binds to the lock, it triggers a response that helps to treat a particular condition. However, the exact lock that medibazine binds to and how it triggers this response is not yet fully understood.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MEDIBAZINE CI brief — competitive landscape report
MEDIBAZINE updates RSS · CI watch RSS

Frequently asked questions about MEDIBAZINE

What is MEDIBAZINE?

MEDIBAZINE is a medibazine drug.

How does MEDIBAZINE work?

Medibazine works by interacting with a specific target in the body to produce a therapeutic effect.

What drug class is MEDIBAZINE in?

MEDIBAZINE belongs to the medibazine class. See all medibazine drugs at /class/medibazine.

What development phase is MEDIBAZINE in?

MEDIBAZINE is in Phase 2.

Drug class: All medibazine drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing